,address1,city,state,zip,country,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,3400 One First Canadian Place,Toronto,ON,M5X 1A4,Canada,https://www.vaxil-bio.com,Biotechnology,Healthcare,"Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","{'maxAge': 1, 'name': 'Mr. Gadi  Levin B.Com., C.A., CPA, M.B.A., MBA', 'age': 49, 'title': 'CEO & Chairman', 'yearBorn': 1973, 'fiscalYear': 2021, 'totalPay': 72383, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.0,2500,2500,11055,6030,6030,0.0,0.0,0,0,1520200,0.0042,0.06,0.013956,0.0140609,0.0,0.0,USD,442768,0.0,136979008,0.08165,0.00014999999,0.006,1.8333333,1672444800,1703980800,1688083200,-564000,-0.01,-0.786,PNK,EQUITY,VXLLF,VXLLF,VAXIL BIO LTD (CA),Vaxil Bio Ltd.,1459344600,America/New_York,EDT,-14400000,0.011,none,1064000,0.008,-563000,0,4.791,4.791,-0.2343,-0.48599997,-564500,-782000,0.0,0.0,0.0,CAD,
1,3400 One First Canadian Place,Toronto,ON,M5X 1A4,Canada,https://www.vaxil-bio.com,Biotechnology,Healthcare,"Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","{'maxAge': 1, 'name': 'Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA', 'age': 70, 'title': 'Chief Financial Officer', 'yearBorn': 1952, 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.0,2500,2500,11055,6030,6030,0.0,0.0,0,0,1520200,0.0042,0.06,0.013956,0.0140609,0.0,0.0,USD,442768,0.0,136979008,0.08165,0.00014999999,0.006,1.8333333,1672444800,1703980800,1688083200,-564000,-0.01,-0.786,PNK,EQUITY,VXLLF,VXLLF,VAXIL BIO LTD (CA),Vaxil Bio Ltd.,1459344600,America/New_York,EDT,-14400000,0.011,none,1064000,0.008,-563000,0,4.791,4.791,-0.2343,-0.48599997,-564500,-782000,0.0,0.0,0.0,CAD,
2,3400 One First Canadian Place,Toronto,ON,M5X 1A4,Canada,https://www.vaxil-bio.com,Biotechnology,Healthcare,"Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.","{'maxAge': 1, 'name': 'Dr. Riva  Kovjazin M.D.', 'title': 'Sr. Scientist & Member of Scientific Advisory Board', 'exercisedValue': 0, 'unexercisedValue': 0}",1640908800,86400,4,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.011,0.0,2500,2500,11055,6030,6030,0.0,0.0,0,0,1520200,0.0042,0.06,0.013956,0.0140609,0.0,0.0,USD,442768,0.0,136979008,0.08165,0.00014999999,0.006,1.8333333,1672444800,1703980800,1688083200,-564000,-0.01,-0.786,PNK,EQUITY,VXLLF,VXLLF,VAXIL BIO LTD (CA),Vaxil Bio Ltd.,1459344600,America/New_York,EDT,-14400000,0.011,none,1064000,0.008,-563000,0,4.791,4.791,-0.2343,-0.48599997,-564500,-782000,0.0,0.0,0.0,CAD,
